|
|
Vaccine Detail
|
MART-1 Fowlpox Vaccine |
| Vaccine Information |
- Vaccine Name: MART-1 Fowlpox Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007503
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: MLANA
- MLANA-Dupli
gene engineering:
- Description: A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas; prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. (NCI04) (NCIT_C2776).
|
| Host Response |
|
|
| References |
Lindsey et al., 2006: Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12(8); 2526-2537. [PubMed: 16638862].
NCIT_C2776: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2776]
|
|
